Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study

Myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients

Rafael G. Amado, Ronald T. Mitsuyasu, Joseph D Rosenblatt, Frances K. Ngok, Andreas Bakker, Steve Cole, Nathalie Chorn, Lii Shin Lin, Gregory Bristol, Maureen P. Boyd, Janet L. Macpherson, Gregory C. Fanning, Alison V. Todd, Julie A. Ely, Jerome A. Zack, Geoff P. Symonds

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

A phase I gene transfer clinical study was undertaken to examine the ability to introduce a potential anti-human immunodeficiency virus (HIV) gene therapeutic into hematopoietic progenitor cells (HPC), thereby contributing to multilineage engraftment. The potential therapeutic effect of genetically modifying HPC with protective genes in HIV-infected adults depends in part on the presence of adult thymic activity and myeloid capacity in the setting of HIV replication. Herein we report the presence and expression of a retroviral vector encoding an anti-HIV-1 ribozyme in mature hematopoietic cells of different lineages, and de novo T-lymphocyte development ensuing from genetically engineered CD34+ HPC. Sustained output of vector-containing mature myeloid and T-lymphoid cells was detected even in patients with multidrug-resistant infection. In addition, the study showed that the degree of persistence of gene-containing cells was dependent on transduced HPC dose. These novel findings support the concept of gene therapy as a modality to effect immune reconstitution with cells engineered to inhibit HIV replication and this report represents the first demonstration of long-term maintenance of a potential therapeutic transgene in HIV disease.

Original languageEnglish
Pages (from-to)251-262
Number of pages12
JournalHuman Gene Therapy
Volume15
Issue number3
DOIs
StatePublished - Mar 1 2004

Fingerprint

Catalytic RNA
Hematopoietic Stem Cells
HIV-1
HIV
Virus Replication
Genes
Therapeutic Uses
Cell Lineage
Virus Diseases
Transgenes
Genetic Therapy
Lymphocytes
T-Lymphocytes
Therapeutics
Infection

ASJC Scopus subject areas

  • Genetics

Cite this

Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study : Myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. / Amado, Rafael G.; Mitsuyasu, Ronald T.; Rosenblatt, Joseph D; Ngok, Frances K.; Bakker, Andreas; Cole, Steve; Chorn, Nathalie; Lin, Lii Shin; Bristol, Gregory; Boyd, Maureen P.; Macpherson, Janet L.; Fanning, Gregory C.; Todd, Alison V.; Ely, Julie A.; Zack, Jerome A.; Symonds, Geoff P.

In: Human Gene Therapy, Vol. 15, No. 3, 01.03.2004, p. 251-262.

Research output: Contribution to journalArticle

Amado, RG, Mitsuyasu, RT, Rosenblatt, JD, Ngok, FK, Bakker, A, Cole, S, Chorn, N, Lin, LS, Bristol, G, Boyd, MP, Macpherson, JL, Fanning, GC, Todd, AV, Ely, JA, Zack, JA & Symonds, GP 2004, 'Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: Myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients', Human Gene Therapy, vol. 15, no. 3, pp. 251-262. https://doi.org/10.1089/104303404322886101
Amado, Rafael G. ; Mitsuyasu, Ronald T. ; Rosenblatt, Joseph D ; Ngok, Frances K. ; Bakker, Andreas ; Cole, Steve ; Chorn, Nathalie ; Lin, Lii Shin ; Bristol, Gregory ; Boyd, Maureen P. ; Macpherson, Janet L. ; Fanning, Gregory C. ; Todd, Alison V. ; Ely, Julie A. ; Zack, Jerome A. ; Symonds, Geoff P. / Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study : Myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. In: Human Gene Therapy. 2004 ; Vol. 15, No. 3. pp. 251-262.
@article{46bd038968af445584f18959eee26c07,
title = "Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: Myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients",
abstract = "A phase I gene transfer clinical study was undertaken to examine the ability to introduce a potential anti-human immunodeficiency virus (HIV) gene therapeutic into hematopoietic progenitor cells (HPC), thereby contributing to multilineage engraftment. The potential therapeutic effect of genetically modifying HPC with protective genes in HIV-infected adults depends in part on the presence of adult thymic activity and myeloid capacity in the setting of HIV replication. Herein we report the presence and expression of a retroviral vector encoding an anti-HIV-1 ribozyme in mature hematopoietic cells of different lineages, and de novo T-lymphocyte development ensuing from genetically engineered CD34+ HPC. Sustained output of vector-containing mature myeloid and T-lymphoid cells was detected even in patients with multidrug-resistant infection. In addition, the study showed that the degree of persistence of gene-containing cells was dependent on transduced HPC dose. These novel findings support the concept of gene therapy as a modality to effect immune reconstitution with cells engineered to inhibit HIV replication and this report represents the first demonstration of long-term maintenance of a potential therapeutic transgene in HIV disease.",
author = "Amado, {Rafael G.} and Mitsuyasu, {Ronald T.} and Rosenblatt, {Joseph D} and Ngok, {Frances K.} and Andreas Bakker and Steve Cole and Nathalie Chorn and Lin, {Lii Shin} and Gregory Bristol and Boyd, {Maureen P.} and Macpherson, {Janet L.} and Fanning, {Gregory C.} and Todd, {Alison V.} and Ely, {Julie A.} and Zack, {Jerome A.} and Symonds, {Geoff P.}",
year = "2004",
month = "3",
day = "1",
doi = "10.1089/104303404322886101",
language = "English",
volume = "15",
pages = "251--262",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study

T2 - Myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients

AU - Amado, Rafael G.

AU - Mitsuyasu, Ronald T.

AU - Rosenblatt, Joseph D

AU - Ngok, Frances K.

AU - Bakker, Andreas

AU - Cole, Steve

AU - Chorn, Nathalie

AU - Lin, Lii Shin

AU - Bristol, Gregory

AU - Boyd, Maureen P.

AU - Macpherson, Janet L.

AU - Fanning, Gregory C.

AU - Todd, Alison V.

AU - Ely, Julie A.

AU - Zack, Jerome A.

AU - Symonds, Geoff P.

PY - 2004/3/1

Y1 - 2004/3/1

N2 - A phase I gene transfer clinical study was undertaken to examine the ability to introduce a potential anti-human immunodeficiency virus (HIV) gene therapeutic into hematopoietic progenitor cells (HPC), thereby contributing to multilineage engraftment. The potential therapeutic effect of genetically modifying HPC with protective genes in HIV-infected adults depends in part on the presence of adult thymic activity and myeloid capacity in the setting of HIV replication. Herein we report the presence and expression of a retroviral vector encoding an anti-HIV-1 ribozyme in mature hematopoietic cells of different lineages, and de novo T-lymphocyte development ensuing from genetically engineered CD34+ HPC. Sustained output of vector-containing mature myeloid and T-lymphoid cells was detected even in patients with multidrug-resistant infection. In addition, the study showed that the degree of persistence of gene-containing cells was dependent on transduced HPC dose. These novel findings support the concept of gene therapy as a modality to effect immune reconstitution with cells engineered to inhibit HIV replication and this report represents the first demonstration of long-term maintenance of a potential therapeutic transgene in HIV disease.

AB - A phase I gene transfer clinical study was undertaken to examine the ability to introduce a potential anti-human immunodeficiency virus (HIV) gene therapeutic into hematopoietic progenitor cells (HPC), thereby contributing to multilineage engraftment. The potential therapeutic effect of genetically modifying HPC with protective genes in HIV-infected adults depends in part on the presence of adult thymic activity and myeloid capacity in the setting of HIV replication. Herein we report the presence and expression of a retroviral vector encoding an anti-HIV-1 ribozyme in mature hematopoietic cells of different lineages, and de novo T-lymphocyte development ensuing from genetically engineered CD34+ HPC. Sustained output of vector-containing mature myeloid and T-lymphoid cells was detected even in patients with multidrug-resistant infection. In addition, the study showed that the degree of persistence of gene-containing cells was dependent on transduced HPC dose. These novel findings support the concept of gene therapy as a modality to effect immune reconstitution with cells engineered to inhibit HIV replication and this report represents the first demonstration of long-term maintenance of a potential therapeutic transgene in HIV disease.

UR - http://www.scopus.com/inward/record.url?scp=12144291445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12144291445&partnerID=8YFLogxK

U2 - 10.1089/104303404322886101

DO - 10.1089/104303404322886101

M3 - Article

VL - 15

SP - 251

EP - 262

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 3

ER -